LIPIGON PHARMACEUTICALS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3595 SEK | +9.94% |
|
+6.05% | -16.59% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Capitalization 1 | 15.99 | 45.45 | 45.45 | - |
| Enterprise Value (EV) 1 | 15.99 | 22.56 | 25.85 | 45.45 |
| P/E ratio | - | - | - | - |
| Yield | - | - | - | - |
| Capitalization / Revenue | 41 x | 3.12 x | 3.07 x | 1.7 x |
| EV / Revenue | 41 x | 1.29 x | 1.75 x | 1.7 x |
| EV / EBITDA | -0.42 x | -1.83 x | -1.39 x | -1.8 x |
| EV / FCF | -426,858 x | - | - | - |
| FCF Yield | -0% | - | - | - |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 20,244 | 126,422 | 126,422 | - |
| Reference price 2 | 0.7900 | 0.3595 | 0.3595 | 0.3595 |
| Announcement Date | 2/28/23 | 2/22/24 | - | - |
1SEK in Million2
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net sales 1 | 4.278 | 0.39 | 17.48 | 14.8 | 26.8 |
| EBITDA 1 | - | -38.11 | -12.35 | -18.6 | -25.2 |
| EBIT 1 | - | -37.74 | -12.37 | -18.6 | -25.2 |
| Operating Margin | - | -9,677.44% | -70.77% | -125.68% | -94.03% |
| Earnings before Tax (EBT) 1 | - | -37.7 | -12.13 | -18.6 | -25.2 |
| Net income 1 | -8.068 | -37.7 | -12.13 | -18.6 | -25.2 |
| Net margin | -188.59% | -9,667.95% | -69.38% | -125.68% | -94.03% |
| EPS | - | - | - | - | - |
| Free Cash Flow | - | -37.47 | - | - | - |
| FCF margin | - | -9,606.92% | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 4/30/21 | 2/28/23 | 2/22/24 | - | - |
1SEK in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - |
| Net Cash position 1 | - | - | 31.9 | 19.6 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | -37.5 | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - |
| Announcement Date | 4/30/21 | 2/28/23 | 2/22/24 | - | - |
1SEK in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -16.59% | 4.15M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- LPGO Stock
- Financials Lipigon Pharmaceuticals AB
